Related Experiment Video
Updated: Dec 16, 2025
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Prognostic Indicators for Gastrointestinal Stromal Tumors: A Review
1Department of Trauma center, The First Hospital of China Medical University, Shenyang, China.
Abstract:
Gastrointestinal stromal tumors (GISTs) are potentially malignancies that can occur anywhere in the digestive tract. Tyrosine kinase inhibitors (TKIs) such as imatinib have proven effective since the discovery of KIT and PDGFRA. The current version of NCNN, ESMO and EURACAN guidelines recognized that the three main prognostic factors are the mitotic rate, tumor size and tumor site. In addition, tumor rupture is also recognized as an independent risk factor. However, recent evidence shows that various types of gene mutations are associated with prognosis, and influencing factors such as gastrointestinal bleeding and high Ki67 index have been associated with poor prognosis. It shows that the current risk classification is still insufficient and controversial. With the emergence of more and more lack mutation in KIT/PDGFRA GISTs (KIT/PDGFRA wild-type GISTs) or drug resistance genes, primary and secondary drug resistance problems are caused, which makes the treatment of late or metastatic GIST face challenges. Therefore, this article will review the clinicopathological characteristics of GIST, the special molecular subtypes and other factors that may affect prognosis. We will also explore reliable prognostic markers for better postoperative management and improve the prognosis of patients with GIST.
Insights
Gastrointestinal stromal tumors (GISTs) have complex prognoses beyond current guidelines. New research explores molecular subtypes and clinical factors to improve risk stratification and patient outcomes for GISTs.
Area of Science:
- Gastrointestinal Oncology
- Molecular Pathology
- Cancer Biomarkers
Background:
- Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms of the digestive tract.
- Tyrosine kinase inhibitors (TKIs) like imatinib are standard treatments, targeting KIT and PDGFRA mutations.
- Current prognostic factors (mitotic rate, tumor size, site, rupture) are insufficient for accurate risk stratification.
Purpose of the Study:
- To review clinicopathological features of GISTs.
- To explore molecular subtypes and novel prognostic factors influencing GIST outcomes.
- To identify reliable markers for improved postoperative management and patient prognosis.
Main Methods:
- Literature review of clinicopathological characteristics of GISTs.
- Analysis of molecular subtypes, including KIT/PDGFRA wild-type GISTs.
- Investigation of factors like gene mutations, tumor rupture, gastrointestinal bleeding, and Ki67 index.
Main Results:
- Existing prognostic factors are insufficient and controversial.
- KIT/PDGFRA wild-type GISTs and drug resistance pose treatment challenges.
- Factors such as specific gene mutations, tumor rupture, gastrointestinal bleeding, and high Ki67 index are associated with poor prognosis.
Conclusions:
- Current risk classification for GISTs needs refinement.
- Understanding diverse molecular subtypes and clinical factors is crucial for personalized GIST management.
- Identification of novel prognostic markers will enhance postoperative strategies and patient outcomes.
More Related Videos
05:16Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
Published on: February 19, 2022
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018